Oncology Targeted Therapies for Acute Leukemia UNIVERSITY OF CALIFORNIALOS ANGELES Catherine F. Clarke Aldana MasangkayGrace IdaliaSmall molecules that can disrupt cell signaling by inhibiting protein-protein interactions hold promise for the development of therapeutics against leukemia. This study tested ...
Until 2000, therapy for chronic myeloid leukemia (CML) was limited to nonspecific agents such as busulfan, hydroxyurea, and interferon-alpha (IFN-a). The landscape changed dramatically with the development of small-molecule tyrosine kinase inhibitors (TKIs) that was shown to potently interfere with...
Targeted therapies in myeloid leukemias. Ann Hematol 2004;83(Suppl. 1):S75-6.John AM, Thomas NSB, Mufti GJ, Padua RA. Targeted therapies in myeloid leukemia. Semin Cancer Biol 2004;14:41-62.John AM,Thomas NS,Mufti GJ,et al.Targeted therapies in myeloid leukemia[J].Semin Cancer Biol,...
Approach to frontline treatment of AML with FDA-approved therapies in 2022. Treatment algorithm of AML induction and maintenance therapy is shown.AMLAcute myeloid leukemia,GOGemtuzumab ozogamicin,MIDOMidostaurin,HMAHypomethylating agent,VENVenetoclax,ENAEnasidenib;IVOIvosidenib,LDACLow-dose cytarabine,alloH...
leukemia remains incomplete, the information gained to date has had a profound impact on the way these malignancies are both diagnosed and monitored during therapy. More recently, targeted therapies have been developed against some of the identified genetic lesions. These therapies have led to ...
Leukemia, targeted therapyThis chapter gathers together many of the major themes of this textbook to identify shared and unique features of myeloid, T-cell, and B-cell malignancies. Therapeutic strategies that link basic...doi:10.1007/978-1-60761-384-8_38...
John DiPersio, MD, PhD, discusses targeted therapies for myeloid malignancies using DARTs, Bites, and antibody–drug conjugates, a topic he presented during the 2019 Society for Hematologic Oncology Annual Meeting. John DiPersio, MD, PhD, chief of the Division of Oncology and direc...
(2010d). Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia, Dec;24(12), pp. 2100-9.Weisberg E, Ray A, Barrett R,Nelson E,Christie AL,Porter D,Straub C,Zawel L,Daley JF,Lazo-Kallanian S,Stone R,Galinsky I,Frank D,et al. Smac mimetics: ...
Multiple myeloma, targeted therapy, potential targets, immune-based therapies, precision medicine Introduction In terms of disease progression, multiple myeloma (MM) develops from a malignant precursor disease, progresses to monoclonal gammopathy of undetermined significance (MGUS), and then to smoldering...
This important path from bench to bedside is very close to Meyer's heart and, in her view, highlights the openness of the hematology field to innovation: "As a clinician and researcher, my focus is clearly on improving therapies. My main motivation is to find something that not only works...